Epidemiological and Clinical Changes in RSV-Associated Pneumonia in Children in Mexico Before and During the COVID 19

Ilen Adriana Diaz-Torres1, Isamu Daniel Cabrera-Takane1, Fanny Yasmin Ortega-Vargas1

  • 1Infectious Diseases Research Laboratory, Research Division, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.

Infectious Disease Reports
|November 24, 2025
PubMed

Insights

Respiratory syncytial virus (RSV) infections in children shifted towards summer and autumn, with increased incidence and older affected children during the COVID-19 pandemic. This highlights changes in RSV epidemiology and seasonality.

Area of Science:

  • Pediatric infectious diseases
  • Epidemiology
  • Virology

Background:

  • Respiratory syncytial virus (RSV) is a major cause of respiratory illness in young children.
  • Public health measures during the COVID-19 pandemic temporarily reduced RSV transmission.
  • An atypical resurgence of RSV was observed in mid-2021.

Purpose of the Study:

  • To compare clinical and epidemiological features of RSV infections in Mexican children before and during the COVID-19 pandemic.
  • To analyze changes in RSV seasonality, incidence, and affected demographics.
  • To identify risk factors for severe RSV-related pneumonia.

Main Methods:

  • Comparative ambispective longitudinal epidemiological study with two cohorts (2010-2013 and 2021-2023).
  • Inclusion of children under five years diagnosed with RSV-related pneumonia.
  • Statistical analyses including t-tests, chi-square, and logistic regression; incidence density calculation.

Main Results:

  • Mean age of affected children increased from 10 to 15 months.
  • RSV activity started earlier (summer months) with higher incidence post-2020.
  • RSV type B became more prevalent (58.5% vs. 3.8%), and co-infections increased (60% vs. 39%).

Conclusions:

  • RSV seasonality has shifted towards summer and autumn.
  • Increased incidence and infections in older children were observed during the pandemic period.
  • Ongoing surveillance is crucial to understand evolving RSV patterns amidst complex public health scenarios.

Related Concept Videos

Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
2.5K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.4K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
765
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
710
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
735
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.1K